SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " utica " 450 found 🔀 AI-powered Shuffle
Global Health & WASH: May 2026 Funding Opportunities (14 new opportunities!)
The May update for Global Health & WASH brings new calls that cluster around three distinct shifts: LMIC research leadership moving from funder encouragement into a hard eligibility constraint, pharmaceutical and corporate-linked funders running structurally independent education and use-inspired research portfolios at substantial scale, and AI adoption shifting decisively from speculative tool to operational capability across health and WASH systems alike. In LMIC Research Leadership as Eligibility, Not Encouragement, Wellcome anchors the dominant signal of the month with three separate major calls that all require or strongly center LMIC leadership in their basic eligibility architecture. Wellcome’s ESIC Hubs (£1.5-£1.9M per hub over 3-5 years) explicitly requires an LMIC-based lead applicant, treating Global South leadership as a design constraint rather than a participation goal. Wellcome’s Infectious Disease Clinical Trial Development Award funds transdisciplinary teams whose lead must be a mid-career or established researcher based at an organization in Africa, South Asia, or Southeast Asia. Wellcome’s larger Infectious Disease Clinical Trial Award (£1M-£8M for optimizing licensed interventions) requires the administering organization to be in eligible LMIC regions and at least 50% of applicants based there. Around Wellcome, the same pattern shows up at smaller scale and across funders: CHINNOVA channels $1M into West and Central African research institutions for climate-health work; IBRO’s Neuroscience Training Grants explicitly tier ceilings by region of residence with Africa receiving the highest amount ($5,000); IHME’s GBD Emerging Researcher Award reserves at least one of its two annual awards for an LMIC researcher; Sidaction’s HIV Cure call funds research teams across France, the Netherlands, and eligible African countries with a minimum two-country collaboration requirement. Taken together, these calls signal a meaningful shift in how research equity is being operationalized — not as encouragement language at the bottom of a call, but as a structural feature of who can lead, where the work must be administered, and what proportion of the team must be regionally rooted. In Pharma-Funded Independent Medical Education and Use-Inspired Research, the lineup this month is unusually deep. Pfizer alone runs four parallel calls under independent education and quality improvement frameworks: a Migraine and Women’s Health RFP (200K x 2-year, $500K pool), Migraine IME ($200K, $1M pool), JAK Inhibitor evidence-based education ($100K), and Maternal Vaccination HCP Education in Saudi Arabia ($75K), plus a separate Pediatric Pneumococcal Surveillance research call in Saudi Arabia ($400K per project). Novo Nordisk Foundation runs four parallel calls of its own at substantial scale: Infectious Diseases Catalyst Grants (DKK 60M pool, up to DKK 7M collaborative), Non-Diabetic Endocrinology Collaborative Grants (DKK 53M pool, DKK 5-10M per project), Pioneer Innovator Grant Health (DKK 1.1M), and Distinguished Innovator Grant Health (DKK 6.8M). LEO Foundation deploys DKK 2-4M per project for dermatology research excellence. Pfizer’s framing across calls deliberately separates the funding from product promotion, emphasizing measurable practice-relevant change and structural distance between scientific outputs and commercial activity. Novo Nordisk’s “use-inspired” hard filter pushes researchers toward a credible translation pathway from mechanism to deployable tool. The pattern: industry-aligned funders are running structurally independent portfolios at meaningful $ that fund implementation evidence, not promotion. In AI as Operational Capability, Not Speculation, several calls this month explicitly treat AI adoption as a near-term operational question with real evidence and governance requirements, rather than a speculative trend to be watched. Wellcome’s ESIC Hubs frames AI as “the accelerator” for evidence synthesis, asking hubs to translate technical innovation into adoption-ready workflows that can match real-world policy timelines. UNICEF Venture Fund’s new Climate Tech for Children’s Health call funds for-profit startups deploying AI, machine learning, and blockchain in low-resource environments, with a strict requirement that solutions must already have a working prototype with promising pilot results. The Water Research Foundation has launched two simultaneous AI calls treating reproducibility, cybersecurity guardrails, and human-in-the-loop deployments as core design constraints rather than nice-to-haves: one on GenAI and Agentic AI in water utilities ($200K), one on alternatives to water shutoffs that explicitly screens for implementation economics evidence. Nordic Innovation’s quantum technology call (NOK 4.5M) extends the same logic into life science and healthcare, demanding consortium-stage projects mature enough to test with real users. TEF-Health offers €300K in subsidized testing infrastructure for European healthcare AI and robotics SMEs. The pattern: funders are converting AI pilots into playbooks, requiring transfer evidence and risk controls before AI can move from experimentation to sector-wide operational practice. For LMIC-based researchers in infectious disease or evidence synthesis, the three Wellcome calls together represent the deepest concentration of LMIC-led research capital in recent memory — pair the Infectious Disease Clinical Trial Development Award (£200K, deadline May 19) as a strategic pipeline feeder into the larger Infectious Disease Clinical Trial Award (£1-£8M, deadline June 2), since the development award functions explicitly as a track into the larger trial scheme. For Nordic researchers, the four Novo Nordisk Foundation calls plus LEO Foundation and Nordic Innovation Quantum represent ~$30M in regional research capital this cycle, all with deadlines clustered in May-August. For WASH practitioners, the three Water Research Foundation calls together (each up to $200K) are a cluster worth reading across — one on AI deployment, one on shutoff alternatives, one rewarding applied innovation — and the strongest applicants will articulate how their work bridges utility operations to policy-relevant evidence. For US-based clinical researchers and educators, the four Pfizer calls plus the APF Portfolio’s 80+ programs form an unusually accessible recurring pipeline; APF’s prohibition on indirect costs is a meaningful structural feature for early-career applicants whose institutions might otherwise absorb significant overhead. Snapshot of New Opportunities Total Estimated Funding Pool: $100 Million+ USD The grants are organized into three categories: Open Calls: Current grant and opportunities with a deadline. Grants are listed by closing date. 39 open opportunities- 14 new! Rolling Applications: current grant and opportunities with rolling applications (but it’s still best to submit as early as possible). 14 rolling opportunities- 1 new opportunity! Long term planning: Grants that have closed their current rounds, but are expected to open new windows. 4 long term opportunities! A quick tip for returning readers: if you want to jump straight to the newest additions, use CTRL F to search for “New!” and navigate quickly to the latest funding opportunities This post is for paid subscribers. This helps support the time and effort it takes to curate and organize these opportunities. Subscribe To keep this accessible to everyone who needs it, we’re happy to offer pay what you can rates. You can find more details here. Open Calls: Migraine Competitive Grant Program: Migraine and Women’s Health (Quality Improvement and/or Research RFP), Pfizer.*Closing soon!* Pfizer, in collaboration with the American Headache Society, is seeking independent quality improvement and research projects that close persistent gaps in migraine care for women across the United States. The funding logic centers on measurable, practice-relevant change: proposals should generate actionable evidence, tools, or system improvements that can be shared and used widely, not just within a single site. Priority areas span menstrual migraine and screening in women’s health settings, the role of hormonal fluctuations across the lifespan, sex-specific risk factors, comorbidities and quality-of-life burden, and disparities in outcomes by race, ethnicity, and socioeconomic status. The call is structured as a two-step competitive process with an initial Letter of Intent, with the strongest concepts expected to translate scientific insight into implementable improvements in diagnosis, management, and equity. Geographies: United States. Who can apply: U.S.-based organizations (not individuals), including professional schools, healthcare institutions, professional organizations, and other entities focused on healthcare improvement. Funding amount: Up to USD $200,000 total over 2 years; total pool USD $500,000. Targeted Sectors / SDGs: Health; Focus areas: migraine, women’s health, quality improvement, clinical research, menstrual migraine, health disparities. Deadline: LOI: May 5, 2026; Full proposal (by invitation): August 28, 2026. Learn more and apply here. This RFP rewards “shareable impact”: the most competitive submissions will pair rigorous methods with a clear plan for system uptake and dissemination beyond the originating institution. ReSSARC: Strengthening the Health Sector and Food Security in the Central African Republic (AID 013381/01/0) Call for Proposals, Italian Agency for Development Cooperation (AICS). *Closing soon!* AICS is seeking a limited set of high-capacity humanitarian partners to deliver an integrated package that stabilizes essential health services while reducing acute malnutrition and strengthening food security resilience in priority areas of the Central African Republic. The funder’s logic is explicitly nexus-based: proposals should meet urgent, life-saving needs while reinforcing local systems, coordination mechanisms, and community-level capacity so results persist beyond the emergency window. AICS emphasizes inclusion and protection outcomes, expecting gender-sensitive design and explicit measures for groups facing compounded vulnerability, including women, children under five, internally displaced people, and people with disabilities. The call also signals a localization pathway, encouraging stronger collaboration with national NGOs and balanced partnerships, alongside clear coordination with existing cluster and humanitarian actors to minimize duplication and improve coverage. Geographies: Central African Republic (Bangui, Ombella-Mpoko, Ouham, Ouham-Pende, Lim-Pende, Lobaye). Who can apply: Non-profit organizations registered with AICS, plus eligible non-profits without an office in Italy that have a pre-existing collaboration agreement with an AICS-listed organization. Funding amount: Total pool EUR €1,800,000; max EUR €800,000 (single applicant) or EUR €1,000,000 (ATS). Targeted Sectors / SDGs: Health; Focus areas: malnutrition prevention and treatment, maternal and child health, community health services, food security and resilience, localization partnerships Deadline: May 5, 2026. Learn more and apply here. This call is structured to reward partners who can link frontline service delivery to system durability and localization, not just short-term coverage gains. Contracts for Innovation in drug and alcohol addiction healthcare, Innovate UK. *Closing soon!* Innovate UK, on behalf of the Office for Life Sciences Addiction Healthcare Goals program, is procuring R&D to accelerate innovations that can improve treatment outcomes, strengthen recovery, and reduce harm and deaths linked to drug and alcohol addiction. The competition is positioned as a market-facing readiness push: selected projects are expected to advance solutions toward later-stage validation, generate evidence of user acceptability and UK market fit, and map credible routes through regulatory and certification requirements. Innovate UK signals a preference for innovations that can be field-tested in relevant UK settings and progressed to TRL 6 or 7, with practical plans for commercialization after contract completion. This structure favors applicants that can execute most work in-house, co-develop with service providers and people with lived experience, and translate technical progress into deployable tools for addiction healthcare delivery. Geographies: United Kingdom. Who can apply: Single organizations of any size (including EU, EEA, or international) leading delivery, with most work and key deliverables carried out in the UK; subcontractors for specialist skills only. Funding amount: GBP £200,000–1.5 million per project (inclusive of VAT); Total pool: GBP £20 million (across two strands). Targeted Sectors / SDGs: Health; Focus areas: Mental Health, Health Systems Strengthening, Research & Development, Technology Access. Deadline: May 6, 2026 (11:00am). Learn more and apply here. This call uses procurement to pull near-market addiction innovations toward operational proof and adoption pathways in UK services.
Binghamton student finds her purpose inside and outside the classroom
Through a Binghamton University public health class and pharmaceutical internship, Camil Ventura ’26 found her calling.
Subnautica 2’s System Requirements Could Have You Diving for a Little Extra RAM Just to Reach 30FPS at 1080p
Unknown Worlds has revealed Subnautica 2's PC system requirements, and they may have players with older PCs diving for more RAM.
Apotex becomes the first Canadian‑based pharmaceutical company to receive Health Canada approval for a generic equivalent of Ozempic®
/PRNewswire/ - Apotex Inc. ("Apotex" or the "Company"), Canada's largest Canadian‑based global health company, today announced that Health Canada has approved...
Subnautica 2's early access system requirements are on the punishing side
Unknown Worlds and Krafton have released the minimum, recommended and ultra system requirements for Subnautica 2.
Subnautica 2's early access has chased a campervanning game about starting fires and hacking PCs into an earlier release
Campervanning game Outbound has moved its release date to avoid clashing with Subnautica 2's early access.
Big Pharma throws support behind Ashley Moody in US Senate race
A number of pharmaceutical companies had their drugs removed from a list slated for price reduction negotiations with Medicare officials, thanks to legislation that Moody supported.
Steam's Most Wishlisted Game Is Skipping PS5 for Now
But it's a miracle Subnautica 2 is launching at all
Subnautica 2 Early Access Has A Launch Date, And It's Very Soon
The underwater sequel is due to be playable in just two weeks
Krafton's removal from Subnautica 2 Steam page "blown up a little bigger than it was meant to", as developers emphasise continued co-publishing support
Krafton has confirmed to Eurogamer that it will continue its collaboration with Unknown Worlds on Subnautica 2 following Steam page debacle.
Subnautica 2 launches in Early Access on May 14
Subnautica 2 will launch in Early Access for Xbox Series and PC via Steam, Epic Games Store, and Microsoft Store on May 14 at 8:00 a.m. PT / 11:00 a.m. ET for $29.99, developer Unknown Worlds Enter…
Unknown Worlds / Subnautica 2 Early Access Cinematic Trailer Released
We’re excited today to debut the Subnautica 2 Early Access cinematic trailer 🎉
Cardinal Health lifts annual profit forecast on strong demand for specialty drugs
Drug distributor Cardinal Health on Thursday raised its 2026 profit forecast range, betting on strong demand for costly specialty medicines and branded drugs at its pharmaceuticals unit.
1,200 Athletes Ready for Special Olympics Summer Games in Utica
Excitement is building as the Special Olympics Summer Games prepare to welcome 1,200 athletes.
Utica's Independence Day Celebration Moves to Harbor Point This Year
The City of Utica is getting ready for its Independence Day celebration with a big change in location.
Sun Pharma signs Definitive Agreement to Acquire Organon
Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated co...
Craft show planned at Christian Heritage School
A Christian Craft Show will be held May 2 in Utica, featuring handmade goods, food, crafts and free children’s activities.
Sheridan College to Host Lecture on Careers in Medical Science Liaison Field
Sheridan College will host a public lecture at 7 p.m. Wednesday, April 29, featuring Jenny McDonald, Ph.D., director and medical science liaison at Novartis Pharmaceuticals Corporation. The event is free and open to the public. The presentation, titled “From Bench to Industry: The Role of Medical Science Liaison,” will take place in Room 153 of […]
Health Care Roundup: Market Talk
Find insight on EssilorLuxottica, Hengrui Pharmaceuticals and more in the latest Market Talks covering Health Care.
Trump unveils deal with Regeneron to lower drug prices as part of most-favored-nation initiative
President Donald Trump on Thursday announced a deal with drugmaker Regeneron to lower the cost of its pharmaceutical products as part of the White House’s signature drug pricing initiative.
Watch live: Trump gives remarks on health care affordability
President Trump is hosting an event at the White House on Thursday afternoon centered on health care affordability. Trump is expected to announce a new deal with pharmaceutical company Regeneron, a…
Rowena Dzorvakpor’s dual degree combines health care, business knowledge
The immigrant from Ghana hopes to use her experiences at Carolina to impact insurance groups or pharmaceutical companies.
Rowena Dzorvakpor’s dual degree combines health care, business knowledge
The immigrant from Ghana hopes to use her experiences at Carolina to impact insurance groups or pharmaceutical companies.
Drug ads face new scrutiny at FDA and on Hill
The U.S. and New Zealand are the only countries that allow direct-to-consumer pharmaceutical advertising.
Molteni Group's Contract Business Thrives: Nautical & Hospitality
Molteni Group sees booming growth in contract, hospitality, and nautical sectors, leveraging long-term projects with luxury DNA and global expertise.
Ryan Reynolds on Business Ventures, Blake Lively and ‘Deadpool’
In part one of this Sunday Sitdown Live, Ryan Reynolds joins Willie Geist in front of a packed crowd to discuss the rapid rise of Wrexham A.F.C., his many business ventures like his Maximum Effort, the young audience he’s found at home for his “Deadpool” franchise and what’s next for the superhero. Reynolds also shares support for his wife Blake Lively and reveals how he is feeling about his upcoming 50th birthday milestone. (Sponsored by More to Parkinson’s and brought to you by Acadia Pharmaceuticals Inc. Venue sponsored by City Winery)
Lena Dunham on New Memoir, Jack Antonoff, Health Issues, More
Writer, director, and actor Lena Dunham joins TODAY’s Jenna Bush Hager and Sheinelle Jones to talk about her new memoir, “Famesick: A Memoir,” where she opens up about her health, experience with fame, and what it means to come of age under the intense scrutiny of Hollywood. Dunham talks about the negative attention she got while starring in “Girls” and how it exacerbated her health issues, reflects on her breakup with Jack Antonoff, and opens up about her battle with pharmaceutical dependency. Dunham also shares the story of how she came to the decision to get a hysterectomy when her endometriosis became unbearable, despite her dreams of being a mother.
Community Routes: Access to Mental Health Care Program Bolsters Services Across Three States
Direct Relief, Teva Pharmaceuticals, and the National Association of Free and Charitable Clinics, or NAFC, today announced a second round of grant funding in the amount of $75,000 to each of 11 fre…
Munson celebrates student accomplishments with exhibits
UTICA — Join Munson in celebrating the artistic accomplishments of their students at Pratt Munson College of Art and Design. Their work will be featured in two juried, mixed media
This Women’s Health Company Is Drawing Takeover Interest. The Stock Is Soaring.
Organon stock jumped after a report said Sun Pharmaceutical Industries is nearing an all-cash deal for the women’s health company.
This Women’s Healthcare Stock Is Up 15% on Reports of a Takeover In the Works
Organon shares surged Friday following reports India’s Sun Pharmaceutical made a bid for the women's healthcare company.
Chinese business ‘hired lobbying firm with ties to Donald Trump Jnr’
Lobbying firm Checkmate helped China’s Grand Pharmaceutical Group beat a US national security challenge, public filings show.
Kansas City health leaders announce new integrated theranostics research and treatment center
The center will unite diagnostics, molecular imaging, radiopharmaceutical production and targeted therapies under one coordinated platform.
Washington’s most powerful drug industry lobbyist is stepping down
Steve Ubl built PhRMA into a more aggressive operation as its longtime leader. The White House has tangled with Ubl and the pharmaceutical industry in its bid to lower drug prices.
Spanberger signs bipartisan bills tied to billions in business investment across Virginia
Gov. Abigail Spanberger on Monday signed a package of economic development bills aimed at securing billions of dollars in private investment and creating thousands of jobs across Virginia, highlighting projects in Southside and Central Virginia tied to manufacturing, energy infrastructure and pharmaceuticals.The legislation supports several major projects announced by the administration in February, including a more than $500 million investment in Pittsylvania County by Avio USA Inc. The company plans to build an 860,000-square-foot manufacturing facility at the Southern Virginia Multimodal Park in the town of Hurt.
Health Care Roundup: Market Talk
Find insight on Eli Lilly, Hansoh Pharmaceutical Group and more in the latest Market Talks covering the Health Care sector.
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know
A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and patented drugs.
Trump signs 100% tariff on brand-name pharmaceuticals
Drug companies that commit to moving production to the U.S. will face a 20% tariff and no tariff if they also agree to lower prices.
Trump expected to impose new tariffs on certain pharmaceutical drugs
President Donald Trump plans to impose new tariffs on pharmaceutical companies that have not struck deals to sell their drugs directly to consumers as part of his “Most Favored Nation” pricing initiative, according to a draft of an order obtained by CNN.
Merck KGaA acquires JSR chromatography business
Merck KGaA has completed its previously announced acquisition of the chromatography business of JSR Life Sciences.
Global Industrie - What are the changes in the health care sector?
Discover the major changes reshaping the global health care sector, driven by geopolitics, innovation and new pharmaceutical industry models.
The future of space business depends on a rocket that keeps blowing up
Dozens of startups working on data centers, mining and pharmaceuticals are hanging on Elon Musk's long-stalled megarocket.
The future of space business depends on a rocket that keeps blowing up
Dozens of startups working on data centers, mining and pharmaceuticals are hanging on Elon Musk's long-stalled megarocket.
THE POLICY PROGNOSIS | Health Supply Chains Are Understudied, Limiting Focus on Patients
Previously, this column has scrutinized the lack of accountability in hospital systems, health insurance companies, pharmaceutical manufacturers, pharmacy benefit managers (PBMs) and their negotiators for raising U.S. health care costs. However, far more financial incentives exist to overcharge consumers for medications and services, and scarcely discussed negotiators may be taking revenues at every stage of...
Pricing, politics and patients: the new drug affordability battle
The USA remains the outlier among wealthy drug markets. OECD data for 2023 put US retail pharmaceutical spending at $1,713 per person, against an OECD average of $766. Germany was at $1,158 and Switzerland at $1,061.
Jack Henke to discuss Oneida Lake history
Historian Jack Henke will present a talk and book signing on Oneida Lake history April 4 at the Oneida County History Center in Utica.
Scientists Figured Out How to Turn Plastic Waste Into a Parkinson's Drug
From pollutants to pharmaceuticals.
How to Turn a Chicken Egg Into a Drug Factory
A biotech start-up is testing a novel way of efficiently producing pharmaceutical drugs.
Boehringer Ingelheim and Connecticut Science Center Launch an Innovation Lab to Advance STEM Education Across Connecticut
/PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Connecticut Science Center announced the launch of an Innovation Lab, presented by Boehringer, a...
Lightning Round: Sell Penn Entertainment
'Mad Money' host Jim Cramer weighs in on stocks including: Qnity Electronics, Rigel Pharmaceuticals, Penn Entertainment, Applied Digital, and more.
Cardinal Health (CAH) Emerged as a Key Contributor on Pharmaceutical Strength and Margin Expansion
Renaissance Investment Management, an investment management company, released its Q4 2025 “Large Cap Growth Strategy” investor letter. A copy of the letter can be downloaded here. The strategy faced a difficult fourth quarter of 2025, underperforming both the S&P 500, which gained 2.7%, and the Russell 1000 Growth Index as market leadership remained concentrated in […]
Grifols Plans IPO of U.S. Biopharma Business
The Spanish pharmaceutical company is looking to raise money to bolster its balance sheet and fund investments.
Imaging manufacturer Guerbet faces financial challenges following recent FDA warning
Regulators recently scolded the France-based pharmaceutical firm for safety issues that occurred at its plant in Raleigh, North Carolina, which produces imaging contrast agents.
Apnimed Announces Strategic Monetization of Shionogi-Apnimed Sleep Science (SASS) Joint Venture Stake for $150M and Royalties, Strengthening Focus on its Wholly-Owned OSA Program, AD109
/PRNewswire/ -- Apnimed, Inc., a pharmaceutical company developing an oral drug product candidate, AD109, that is designed to address a root cause of...
Formulating a Future: Finding a Calling in Pharmaceutical Science | Oberlin College and Conservatory
Chemistry major Alex Xie ’26 utilizes CELA’s research fellowships and scholarship advising to transition from campus labs to a future in pharmaceutical research.
Utica University Science Fair Inspires Young Scientists
Young scientists from local middle and high schools gathered for the 47th annual Utica University Regional Science Fair.
47th annual Utica University science fair shows area students are smarter than ever
Four dozen science projects from 60 students from eight area schools competed for the top prizes at the Donohue Concourse underneath the Frank Gannett Library. Some of the topics may have changed over the years — there were no baking soda volcanoes — but the students still displayed their projects on decorated posterboard for staff, family and the judges to see. The projects were split between the junior division — 7th and 8th grades — and the senior division — 9th through 12th grades.
More Subnautica 2 legal trouble brewing amid claims Krafton "intentionally leaked" May release without consulting reinstated CEO
Lawyers for Subnautica 2 studio's newly reinstated CEO are reportedly pushing for Krafton to be found in contempt of court after it "leaked" a May release.
Utica Zoo Celebrates Spring and Ramadan with Special Events
Families and friends are invited to celebrate the first day of spring and the end of Ramadan with a day full of activities at the Utica Zoo.
Unknown Worlds co-founders' lawyers accuse Krafton of "intentionally leaking" Subnautica 2 release date
"Krafton self-servingly announced the launch without any regard to its impact on the game, the team, or the community," say lawyers
CEO transition puts pharma business in the driver’s seat at Aptar
The company that turned the condiment world upside-down is now turning drug delivery on its nose at the same time it elevates its pharmaceutical leader to CEO.
New dispute emerges around Subnautica 2’s early access release
Lawyers for the ousted—and now partially reinstated—leadership team of Unknown Worlds, the studio behind Subnautica 2, are crying foul over news that the game will be released into early access in May. The release announcement earlier this week was made improperly, potentially “damaging the game and sowing additional confusion among the Subnautica community,” the lawyers said in a letter sent on Tuesday to Vice Chancellor Lori Will of Delaware’s Court of Chancery. In their letter, the lawyers also floated the idea of asking Will to find Krafton in contempt of the court’s ruling. The letter was sent just one day after Will’s bombshell ruling that publisher Krafton had breached its contract with Unknown Worlds’ executive team, when it fired them last June. The new issue isn’t necessarily the May early access timeframe, but how the news was announced. The letter and Krafton’s response have not been previously reported. A quick recap of prior events: Subnautica 2 is an unreleased, underwater survival adventure and the most-wishlisted game on Steam. Last year, longtime Unknown Worlds CEO Ted Gill, along with studio co-founders Charlie Cleveland and Max McGuire, were fired by Krafton. They swiftly sued, saying the publisher had terminated them to avoid paying out up to $250 million in potential performance-based bonuses. The studio leaders had hoped to earn that with an early access release of the game, which Krafton had blocked. The publisher argued in court that Subnautica 2 wasn’t ready, which the ousted execs disputed. On Monday, Will ruled that Krafton had violated its contract, firing the execs to avoid the performance payouts, and that it had to reinstate Gill and give him full authority over any early access release for Subnautica 2. On Tuesday, IGN reported on a new memo issued that day to Unknown Worlds staff by Steve Papoutsis, the executive Krafton had put in charge of Unknown Worlds after the 2025 firings. In the note, Papoutsis said that Subnautica 2 had passed a key development milestone “last week” and that he and Krafton had determined the game “is ready for Early Access release in May.” This news appeared to catch the lawyers for Gill, Cleveland and McGuire by surprise. On Tuesday night, they sent a letter to Will expressing “serious concerns” about whether it would be possible to forge an agreement with Krafton consistent with the judge’s order. Papoutsis’ memo was a problem, they wrote. He didn’t have the authority to declare anything about Subnautica 2’s release. As of 9am ET on Monday, March 16, the effective date of Will’s order, Papoutsis wasn’t CEO of Unknown Worlds. Gill was. And, per Will’s order, only Gill could make Subnautica 2 release decisions. They continued: Krafton self-servingly announced the launch without any regard to its impact on the game, the team, or the community—let alone this Court’s Opinion. Announcing the release of a game is momentous, and it is typically accompanied by significant marketing activity, fanfare, and community coordination. And most importantly, the announcement is carefully designed to maximize excitement for the game. That entire process was supposed to be driven by Mr. Gill. However, in defiance of the Court’s Opinion, Krafton has now taken that away, further damaging the game and sowing additional confusion among the Subnautica community. The lawyers speculated that Krafton had “intentionally leaked” Papoutsis’ memo and then issued an official statement to confirm the leak. Game File is a reader-supported publication. My reporting is only possible through support from readers like you. To support my work, consider becoming a free or paid subscriber. Subscribe On Wednesday, lawyers for Krafton defended their client in their own letter to vice chancellor Will, saying nothing they did violated her order nor showed contempt: Papoutsis’s message was simply celebrating the UW employees’ efforts toward a past event: Krafton’s pre-Opinion determination that Subnautica 2 was ready for Early Access release. There was nothing improper about conveying the results of the milestone review or thanking the development team for their dedication and talent. They added that Gill could still make his own call about Subnautica 2’s release: In his role as CEO, Gill will be able to assess independently his views on the state of Subnautica 2 and the appropriate release schedule; nothing in Papoutsis’s message alters Gill’s authority or discretion. Vice chancellor Will has not responded to the letters and doesn’t necessarily have to. Both parties were previously ordered by Will to confer this week and submit a proposed judgment consistent with her ruling. The letter from Gill’s attorney’s this week doesn’t indicate whether he would or would not support a May release for Subnautica 2. But it could limit his options. And, if Gill’s lawyers are right, the lack of marketing fanfare around the leak of the May date could dull the launch of the game. Any harm to Subnautica 2’s launch is an extra sensitive issue given the context of the legal dispute: millions of dollars of payouts are on the line, tethered to the scale of the game’s initial performance. In her ruling on Monday, Will noted that there was obvious “bad blood” between Gill’s side and Krafton but that the two would need to work together: “They can—and must—act in good faith to navigate their remaining contractual relationship.” Item 2: A new kind of couch co-op game A highlight of GDC each year is the Alt.Ctrl showcase that features games played with extremely experimental controllers. Perusing this year’s offerings last Friday, I found a game controlled with giant scissors, another with big toothbrushes and one that amounted to dumpster diving. My favorite was Pivot, a co-op game about collectively maneuvering a couch. It was developed by students at the University of Utah’s masters of arts and engineering games program. Players lift and tilt the physical couch in order to control the position of a virtual one. That virtual one is moving through an obstacle course on-screen, while being pursued by a giant skull. Developer Nishant Verma told me at GDC that the couch is made of styrofoam (this became more evident as I watched!) and that the name was a riff on an episode of the sitcom Friends. Item 3: In brief… 🚫 Ubisoft is laying off more than 100 workers at its Red Storm studio, as the North Carolina location known for decades for its Tom Clancy games, ceases in-house game development, VGC reports. 👀 On Monday, Nvidia’s revealed its DLSS 5 AI-driven graphics technology that purports to improve game graphics… and it has been roasted about it by the media and the online gaming public for the remainder of the week. The tech changed the faces of characters in footage from Resident Evil Requiem, Hogwarts Legacy and EA Sports FC, drawing accusations of giving carefully art-directed games the generic look of AI “slop.” Nvidia CEO Jensen Huang had said on Monday that “DLSS 5 is the GPT moment for graphics—blending handcrafted rendering with generative AI to deliver a dramatic leap in visual realism while preserving the control artists need for creative expression.” By mid-week, Huang was telling Tom’s Hardware that the new tech’s critics were “completely wrong” because game-makers could still “fine-tune the generative AI” to suit their game’s aesthetics.
SK pharmteco Reaffirms Three-Business-Unit Strategy, Strengthens Global Gene Therapy Business Unit with Funding Commitment
RANCHO CORDOVA, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- SK pharmteco today announced a significant funding commitment to support strategic initiatives within its viral vector business, while reaffirming its long-term growth strategy across three business units: small molecule, peptides, and viral vectors. SK pharmteco is sharpening its strategy to provide pharmaceutical and biotechnology partners with the financial strength, technical rigor, and operational infrastructure needed for long-term
Utica Comets Host Speedway Night
Racing fans and hockey fans will come together for a unique event at the Adirondack Bank Center.
Stada Hunts for Major Consumer Health Deal After Record Profit
German pharmaceutical firm Stada said it’s ready to make a major consumer health acquisition as it books record profit and transitions to new ownership.
Subnautica 2 publisher’s CEO used ChatGPT in failed bid to avoid paying US$250m bonus to own studio head, court hears
Court orders Krafton’s CEO to reinstate Unknown Worlds’ leadership after they were ousted using an AI-generated plan
Subnautica 2 might finally be entering early access in May
Subnautica 2 has weathered the storm and has rescheduled its early access release.
Celebrating St. Patrick’s Day
A look at how St. Patrick’s Day has evolved in the City of Utica.
Subnautica 2 Will Finally Enter Early Access in May Following Year of Delays and Legal Drama
Subnautica 2 is entering early access at last. IGN can exclusively reveal that both developer Unknown Worlds and publisher Krafton have agreed the game is ready for its early access release in May on Xbox and PC, though an exact date hasn't been provided just yet.
Limited Tickets for Utica's Food and Art Unite This Sunday
Food and Art Unite will bring together Utica’s diverse communities for a celebration of art, music, culture and cuisine at Munson in Utica.
A gaming CEO asked ChatGPT how to avoid paying a $250 million bonus. It didn’t work
Krafton's AI-assisted scheme to oust the makers of Subnautica 2 just collapsed in court after a judge ruled the company had to reinstate the CEO and payout the bonus.
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
CAMBRIDGE, England & BOSTON, March 17, 2026--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided recent corporate updates.
Krafton responds to Subnautica 2 legal ruling: "we are evaluating our options as we determine our path forward"
Krafton has issued a statement in response to a legal ruling yesterday, which pushed for CEO Ted Gill to be reinstated to the Subnautica 2 studio.
CEO Asks ChatGPT How to Void $250 Million Contract, Ignores His Lawyers, Loses Terribly in Court
The CEO of Krafton used ChatGPT to push out the head of the studio developing Subnautica 2 against the advice of his own legal team and failed miserably.
Bombshell judgment demands Krafton immediately reinstate ousted CEO and return his authority over Subnautica 2
In a bombshell ruling, a court has ordered Krafton to reinstate former Unknown World CEO Ted Gill, return control of th…
Judge orders Subnautica 2 bosses be handed back control of company after Krafton found guilty of "wrongfully usurping control"
A judge has ruled in favour of the Subnautica 2 developers fired by publisher Krafton.
Subnautica 2's Publisher Used ChatGPT For Legal Advice In Messy Court Battle
A judge has explained how the CEO of Krafton relied on an AI chatbot for legal advice and planning
Judge delivers bombshell order for Krafton to reinstate fired Subnautica 2 devs and CEO, putting $250m bonus package back on the table
A judge has ruled that fired Subnautica 2 leads including the former Unknown Worlds CEO must be reinstated, with their $250m bonus package extended.
Judge Orders Subnautica 2 Studio CEO Reinstated Amid Lawsuit
Krafton is "enjoined" from firing Ted Gill as part of a new court order
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights
MOUNTAIN VIEW, Calif., March 16, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the full year ended December 31, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates.
Community's Choice Awards spotlight: V&V Carpet Care
Almost out the door! Best of Mohawk Valley Community’s Choice Awards nominations are closing fast.
St. Patrick's Day Parade in Utica Gets Its Iconic Green Line
The green line that guides Utica’s St. Patrick’s Day Parade has returned on Genesee Street.
Scientists Discover Where Drug Residues End Up Inside Crops
Scientists discovered that crops exposed to trace pharmaceuticals in recycled water mostly stash the compounds in their leaves—not the parts we usually eat.
Dassault reveals Falcon 10X with largest cabin in business aviation
Dassault Aviation has unveiled the Falcon 10X ultra-long-range business jet with spacious cabin and a 7,500-nautical-mile range.
Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25
Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the Company will release full year 2025 financial results and provide business updates on Wednesday, March 25, 2026. The Company will host a conference call to discuss results that day at 4:30 PM ET.
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia is planned for Q2 2026, with topline data anticipated in 2H 2027BURLINGTON, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today provided business updates and reported financial results for the fourth quarter and year ended Decembe
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and...
Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment
$250,000 top award goes to Connor Hill in America’s longest running and most distinguished science and math competition Top $250,000 Regeneron Science Talent Search Winner Named Regeneron and Society for Science announced that Connor Hill, 17, of State College, Pennsylvania, won the top award of $250,000 in the 2026 Regeneron Science Talent Search (STS), a program of Society for Science. TARRYTOWN, N.Y. and WASHINGTON, March 10, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. and Societ
Getting Ready for the St. Patrick's Day Parade in Utica
Parade week is bringing excitement to the City of Utica as preparations continue for the St. Patrick's Day celebration.
Oneida County awarded $60K to support first responder mental health
Oneida County has been awarded a grant to implement a comprehensive wellness initiative designed to support first responders and uniformed personnel.
Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update
GLEN ALLEN, Va., March 06, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2025 fiscal year ended December 31, 2025. Key Highlights: Regulatory Progress: Achieved positive clinical study results from the AD04-103 pharmacokinetics (P
Health Care Roundup: Market Talk
Find insight on Bayer, Neuren Pharmaceuticals , and more in the latest Market Talks covering Health Care.
The science of structures: FSU chemist synthesizes complex molecule with potential for medicine, pharmaceutical applications
A Florida State University chemist has developed a method to rapidly assemble significantly complex natural molecules with potential in biomedical
$150K Grant for Utica Woman- and Minority-Owned Businesses
Grant funding is now available for woman- and minority-owned businesses with five or fewer employees located in the City of Utica.
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress
ROCKVILLE, Md. & EDMONTON, Alberta, February 26, 2026--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and twelve months ended December 31, 2025 and provided an update on recent business progress.
St. Patrick's Day Parade Week Events in Utica Announced
Utica is set to celebrate St. Patrick’s Day with a week of events and traditions that highlight Irish culture and community spirit.
MVHS Medical Offices Moving to State Street in Utica
Several Mohawk Valley Health System medical offices are moving to a new location in Utica.
San Diego Festival of Science and Engineering brings industry leaders to Petco Park
Exhibitors include Ballet Folklorico Moncayo, Children’s Museum of Discovery and the U.S. Navy, plus major pharmaceutical companies like Bristol Myers Squibb and Genentech among others.
AbbVie to invest $380 million to expand US manufacturing in Illinois
AbbVie on Monday said it would invest $380 million to build two new active pharmaceutical ingredient manufacturing facilities at its Illinois campus, expanding its domestic production capacity for its neuroscience and obesity medicines.